Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 12/20 | 0.69 |
| ▸ | TACR3 | P29371 | 11/20 | 0.69 |
| ▸ | TRPV4 | Q9HBA0 | 9/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461272 | 0.92 | TACR2 (0.66) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL5459917 | 0.82 | TACR2 (0.66) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL5459908 | 0.82 | TACR2 (0.66) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL5908755 | 0.81 | TACR2 (0.70) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL27745647 | 0.81 | TACR2 (0.73) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL5462972 | 0.80 | TACR2 (0.65) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL5470966 | 0.80 | TACR2 (0.63) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL5463541 | 0.80 | TACR2 (0.63) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL5909002 | 0.79 | TRPV4 (0.65) | TACR2TACR3TRPV4OPRM1 | |
| SCHEMBL5460353 | 0.79 | TACR2 (0.63) | TACR2TACR3TRPV4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | KCNK3, KCNQ3, ACKR3 | TACR2 16/4885TACR3 41/4885TRPV4 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.